Review

Metabolic drivers of Alzheimer's disease pathogenesis: Impairments in glucose utilization, lipid homeostasis, and alternative substrate metabolism.

S. Chaudhary Shreya Verma Vidisha Kumari Meghana Tare

2026 · International review of neurobiology · Vol 187, pp. 349-383 · 0 citations

Medicine

TL;DR

Taken together, these metabolic health changes not only reshape the understanding of AD but also open potential prospects for early detection through metabolic biomarkers and for novel therapeutic strategies targeting mitochondrial bioenergetics, glucose restoration, and ketogenic interventions.

DOI PubMed Semantic Scholar

View source

Similar papers

Review 2026

Metabolic therapeutic targets in Alzheimer's disease.

This chapter examines key metabolic pathways implicated in AD, including cerebral glucose hypometabolism, brain insulin resistance, impaired glycolysis, mitochondrial oxidative phosphorylation deficits, oxidative stress, and altered mitochondrial dynamics, and discusses therapeutic strategies aimed at restoring metabol...

Ignatius Raymond Peter L, Debojyoti Chatterjee, A. F. Chrishone et al. · International review of neur... · 0 citations

Review 2026

Brain lipid dysregulation as a driver of energy metabolism failure in Alzheimer's disease.

This chapter addresses the gap and consolidates existing information connecting lipid modifications to metabolic dysfunction in AD, emphasizing molecular pathways and prospective treatment strategies aimed at lipid metabolism to re-establish bioenergetic equilibrium.

Nitin Yadav, Jyotirmoy Banerjee, Manisha Tiwari et al. · International review of neur... · 0 citations

Review Open access Sep 2026

Roles of glycolytic and pyruvate metabolism enzymes in Alzheimer’s disease glycometabolic reprogramming and their therapeutic potential

Current evidence regarding the dysregulation of major glycolytic and pyruvate-metabolizing enzymes, including hexokinase (HK), phosphofructokinase-1 (PFK1), pyruvate kinase (PK), lactate dehydrogenase (LDH), and the pyruvate dehydrogenase complex (PDHc), in both neurons and glial cells are synthesized.

Min-Min Chen, Chang-Min Zuo, Run-Zhi Li et al. · Discover Neuroscience · 0 citations

Review 2026

Metabolic dysregulation in Alzheimer's disease: Mechanisms, markers, and therapeutic prospects.

The chapter outlines the current evidences on dysregulated metabolic processes, and highlights emerging metabolic biomarkers that are identified through advanced neuroimaging modalities, plasma/cerebrospinal fluid (CSF) profiles, lipidomic signatures and markers of mitochondrial impairment, underscoring their diagnosti...

Radhika Mittal, Priya, Jyotirmoy Banerjee et al. · International review of neur... · 0 citations

Review 2026

Energetic crisis, mitochondrial vulnerability and disruption of lactate shuttle in Alzheimer's disease.

Cerebral bioenergetic metabolic failure as a central driver of cognitive decline, arising from irreversible reactive gliosis and neuroblastosis mechanisms is emphasised and various therapeutic options are highlighted, including restoration of ANLS to mitigate the pathogenesis and memory loss in AD.

Gowsika Baskar, Mahesh Kandasamy · International review of neur... · 2 citations

Review Sep 2026

From systems to cells: metabolic mechanisms underlying risk divergence in Alzheimer's disease and amyotrophic lateral sclerosis.

Epidemiological studies show an inverse relationship between metabolic disorders and two major neurodegenerative diseases, Alzheimer's disease (AD) and amyotrophic lateral sclerosis (ALS). Obesity, type 2 diabetes (T2DM), and reduced physical activity increase AD risk, whereas in ALS cardiometabolic factors, particular...

A. Knezović, Antonia Krsnik, J. Homolak et al. · Neuroscience and Biobehavior... · 0 citations